Is INCR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of INCR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate INCR's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate INCR's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for INCR?
Key metric: As INCR is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
The above table shows the Price to Sales ratio for INCR. This is calculated by dividing INCR's market cap by their current
revenue.
What is INCR's PS Ratio?
PS Ratio
0.8x
Sales
₪272.67m
Market Cap
₪228.92m
INCR key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Sales vs Industry: INCR is good value based on its Price-To-Sales Ratio (0.8x) compared to the US Pharmaceuticals industry average (2.5x).
Price to Sales Ratio vs Fair Ratio
What is INCR's PS Ratio
compared to its
Fair PS Ratio?
This is the expected PS Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
INCR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio
0.8x
Fair PS Ratio
n/a
Price-To-Sales vs Fair Ratio: Insufficient data to calculate INCR's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.